These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29417233)

  • 1. Non-profit Drug Research and Development at a Crossroads.
    Jarosławski S; Toumi M; Auquier P; Dussart C
    Pharm Res; 2018 Feb; 35(3):52. PubMed ID: 29417233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-profit drug research and development: the case study of Genethon.
    Jarosławski S; Toumi M
    J Mark Access Health Policy; 2019; 7(1):1545514. PubMed ID: 30479703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health.
    Sadeghi AH; Koldeweij C; Trujillo-de Santiago G; Tannazi M; Hosseinnia N; van Loosbroek O; Manbachi A; Taverne YJHJ; Bogers AJJC; Alvarez MM
    Front Public Health; 2021; 9():541191. PubMed ID: 34660499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
    Sarpatwari A; Kesselheim AS
    J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
    [No Abstract]   [Full Text] [Related]  

  • 7. Affordable orphan drugs: a role for not-for-profit organizations.
    Davies EH; Fulton E; Brook D; Hughes DA
    Br J Clin Pharmacol; 2017 Jul; 83(7):1595-1601. PubMed ID: 28109021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.
    Thielen FW; Heine RJSD; Berg SVD; Ham RMTT; Groot CAU
    Cytotherapy; 2022 Dec; 24(12):1245-1258. PubMed ID: 36216697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should the United States government regulate prescription prices? A critical review.
    Patterson JA; Carroll NV
    Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why High Drug Pricing Is A Problem for Research Ethics.
    Hey SP
    J Bioeth Inq; 2020 Mar; 17(1):29-35. PubMed ID: 31858385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines.
    Suleman F; Low M; Moon S; Morgan SG
    BMJ; 2020 Jan; 368():l4408. PubMed ID: 31932324
    [No Abstract]   [Full Text] [Related]  

  • 12. Profit pools: a fresh look at strategy.
    Gadiesh O; Gilbert JL
    Harv Bus Rev; 1998; 76(3):139-47. PubMed ID: 10179649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pricing behavior of non-profit agencies. The case of blood products.
    Jacobs P; Wilder RP
    J Health Econ; 1984 Apr; 3(1):49-61. PubMed ID: 10266615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical drug development: high drug prices and the hidden role of public funding.
    Annett S
    Biol Futur; 2021 Jun; 72(2):129-138. PubMed ID: 34554467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why stents are expensive: Drivers of high prices in emerging markets.
    Pandey N; Thombal AE
    Health Mark Q; 2018; 35(4):298-312. PubMed ID: 30596465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research on Pricing and Service Level Strategies of Dual Channel Reverse Supply Chain Considering Consumer Preference in Multi-Regional Situations.
    Kang Y; Chen J; Wu D
    Int J Environ Res Public Health; 2020 Dec; 17(23):. PubMed ID: 33297517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pricing of pharmaceuticals is becoming a major challenge for health systems.
    Morgan SG; Bathula HS; Moon S
    BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.